Inventor · disambiguated record
Sanjeeva P. Reddy
Also filed as: REDDY SANJEEVA · REDDY SANJEEVA P
10 granted patents·5 pending applications·17 citations·filing 2006–2022
86Inventor score
Top patents by PatentIndex Score
15 records- 0190US11103491B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2020·Granted Aug 31, 2021·2 cites·12 claims
- 0284US10751332B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2016·Granted Aug 25, 2020·2 cites·7 claims
- 0382US10471051B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2017·Granted Nov 12, 2019·3 cites·38 claims
- 0482US10188654B2Uses of pyrimido-pyridazinones to treat cancerASANA BIOSCIENCES LLC·Filed 2016·Granted Jan 29, 2019·3 cites·17 claims
- 0582US9896445B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2016·Granted Feb 20, 2018·3 cites·27 claims
- 0680US9499495B2Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathwaysASANA BIOSCIENCES LLC·Filed 2014·Granted Nov 22, 2016·4 cites·43 claims
- 0776US11925629B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2021·Granted Mar 12, 2024·0 cites·14 claims
- 0872US2021113578A1Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathwaysASANA BIOSCIENCES LLC·Filed 2020·Application pending·0 cites
- 0970US10912779B2Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathwaysASANA BIOSCIENCES LLC·Filed 2019·Granted Feb 9, 2021·0 cites·23 claims
- 1058US10226468B2Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathwaysASANA BIOSCIENCES LLC·Filed 2017·Granted Mar 12, 2019·0 cites·35 claims
- 1158US9757382B2Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathwaysASANA BIOSCIENCES LLC·Filed 2016·Granted Sep 12, 2017·0 cites·25 claims
- 1258US2024316046A1Erk1/2 inhibitor combination therapyASANA BIOSCIENCES LLC·Filed 2022·Application pending·0 cites
- 1352US2019070182A1Uses of pyrimido-pyridazinones to treat cancerASANA BIOSCIENCES LLC·Filed 2018·Application pending·0 cites
- 1449US2023027072A1Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2ASANA BIOSCIENCES LLC·Filed 2020·Application pending·0 cites
- 1545US2011195110A1Urea compounds useful in the treatment of cancerSMITH ROGER·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →